High-quality business currently experiencing weak market structure. Monitor for trend reversal. Valuations remain demanding and supported by current metrics.
SENTINEL REVIEW
PI Industries Limited (PIIND)•Updated today
🚨 Structural Deterioration Signature: In FY2026, PI Industries Limited is experiencing severe operating deterioration, marked by a 20.4% YoY decline in reported net profit to ₹1,320.8 Cr and a 475 bps compression in EBIT margins to 18.4%. Profitability is being eroded by structural inefficiencies, with operating cash flows contracting 66.5% YoY to ₹474.0 Cr and a persistent 13.1% operating leverage gap. This earnings quality crisis is compounded by operational friction: inventory-revenue divergence of 16.4% stands against a 15.6% revenue contraction, while receivable days rose 43.5% to 129.0. Against this liquidity strain, total debt expanded 113.3% YoY to ₹238.3 Cr, reducing interest coverage to 1.86x and entering Flagium's heightened surveillance range.
- ✓Risk score improved (QoQ change: 0 pts)
- ✗Profitability margins remain stressed
- ✓Universal Inventory Divergence resolved this quarter (11.5 pts)
- ✗New risk trigger: Industrial Margin Stress (+14.8 pts)
- ✗Growth expectations are demanding
- ✗Market structure is declining (Stage 4)
- ✗A/D flow regime is Strong Distribution (-9.25σ)
- ✗Share price is down -23.4% this quarter (from ₹2,310 on 30 Sept to ₹1,770)
- 🔴Investigate Profit Collapse and balance sheet impact
- 🟢Universal Inventory Divergence resolved in latest filing; verify sustainability in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 16.2 ptsGovernance
- 10.0 ptsGrowth Sustainability
- 8.3 ptsEarnings Quality
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | -16.11% | +2.9% | -19.02% |
| 1 Month | -21.33% | -3.36% | -17.98% |
| 6 Months | -43.1% | +6.04% | -49.14% |
| 1 Year | -51.87% | +11.85% | -63.71% |
| 2 Year | -60.76% | +45.28% | -106.04% |
| 3 Year | -48.67% | +126.19% | -174.85% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Pressure has stabilized in governance. This suggests the risk profile is currently stabilizing. No major change in risk trend.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 0 → 35 over 12 quarters.
- Operating profit margins
Risk Drivers (Active Warnings)
Primary Driver & Insights
Governance Integrity Shock is currently the primary contributor to forensic pressure. Ongoing monitoring of cash generation and balance sheet quality is warranted in upcoming quarters.
Active Risk Objects (13)Free Preview (2 of 13)
PIIND: Key governance event detected: DIRECTOR_RESIGNATION.
Governance risk is elevated. Monitor board actions and promoter alignment.
PIIND: EBITDA margin compressed by 1559 bps YoY.
Early signs of margin erosion. Input costs are beginning to eat into core profits.
Unlock All 13 Forensic Signals (11 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 13 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for PI Industries Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for PI Industries Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk profile remained steady this quarter, as emergence of Industrial Margin Stress (+14.8 pts) was offset by improvement in Universal Inventory Divergence (-11.5 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated materially (+17.0 pts), driven by new Working Capital Expansion (+10.8 pts) and new Operating Leverage Stress (+6.4 pts).
Risk improved notably (-11.0 pts), driven by Inventory Stress (-18.0 pts) and Relative Growth Weakness (-17.8 pts), partially offset by new Operating Leverage Stress (+13.2 pts) and new Governance Integrity Shock (+13.0 pts).
Business Resilience & Benchmark Context
Overall: HEALTHYPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Stable
Stable
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for PI Industries Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·10 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Trade Receivables(₹ Cr) | 2,320 | 1,833 | 1,091 | 838 | — | — | — | — | — | — |
Inventories(₹ Cr) | 1,217 | 984 | 1,301 | 1,398 | — | — | — | — | — | — |
Trade Payables(₹ Cr) | 974 | 1,210 | 1,148 | 838 | — | — | — | — | — | — |
Net Working Capital(₹ Cr) | 2,563 | 1,606 | 1,244 | 1,398 | — | — | — | — | — | — |
Working Capital / Sales(%) | 36.5% | 19.3% | 15.8% | 21.0% | — | — | — | — | — | — |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 133d | 70d | 58d | 77d | — | — | — | — | — | — |
Debtor Days (DSO)(days) | 121d | 80d | 51d | 46d | — | — | — | — | — | — |
Inventory Days (DIO)(days) | 63d | 43d | 60d | 77d | — | — | — | — | — | — |
Creditor Days (DPO)(days) | 51d | 53d | 53d | 46d | — | — | — | — | — | — |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | +42.2% | +62.3% | +11.8% | — | — | — | — | — | — | — |
Inventory Growth vs Sales (Δ)(%) | +39.3% | -30.1% | -25.3% | — | — | — | — | — | — | — |
Asset Growth vs Sales (Δ)(%) | +25.1% | +8.4% | +8.6% | — | — | — | — | +14.1% | +9.4% | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | 847 | 247 | -354 | -272 | 315 | — | — | 49 | 120 | -55 |
Accrual Ratio (Accruals / Avg Assets)(%) | 6.6% | 2.1% | -3.7% | -3.2% | — | — | — | 2.0% | 5.7% | -2.8% |
Operating Cash Realisation (CFO / EBITDA)(%) | 29.9% | 66.1% | 108.1% | 104.4% | 51.4% | — | — | 64.3% | 61.1% | 84.4% |
Capitalisation Intensity (CWIP / Assets)(%) | — | — | — | — | — | — | — | — | — | — |
Industry Intelligence
Chemicals KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
| Q2 FY2027 | 55.2% | -620 bps ↓ Profitability contraction | +80 bps ↑ Operating efficiency gains | 48.5% | |
| Q2 FY2027 | 16.7% | -770 bps ↓ Profitability contraction | -1520 bps ↓ Profitability contraction | 15.5% | |
| Q2 FY2027 | 0.13x | — → Stable asset efficiency | -13.3% ↓ Asset utilization moderating | 1.15x | |
| Q2 FY2027 | 469 days | — | +5.9% ↑ Inventory buildup pressure | 48 days |
Understanding Chemicals KPIs
Concall & Management Takeaways
Q1 FY27The call focused on PI Industries’ innovation-led growth, expansion into adjacencies, and resilience despite industry headwinds, with management forthcoming about both opportunities and challenges.
Guidance & Outlook
Management reiterated confidence in a positive growth trajectory for FY27, expecting recovery in exports and scale-up in pharma and biologicals, while maintaining discipline in capital allocation and margins.
“We expect FY27 to be better over FY26 driven by recovery in exports in second half supported by new product launches and gradual scale up of pharma and global biologicals.”
Innovation & R&D
PI emphasized its investments in R&D, new molecule launches, and differentiated capabilities as the foundation for long-term value creation and competitive advantage.
“Our first NCE, Pioxaniliprole, an insecticide, discovered in India, for Indian farmers and now to go to global farmers is set to launch in the domestic market very soon awaiting regulatory approvals.”
Biologicals Expansion
The company highlighted aggressive growth in biologicals, successful field trials, and positive feedback in global markets, positioning biologicals as a key growth driver.
“Biologicals have shown an aggressive growth of 50% with a three-year CAGR of 15%.”
Exports & Operating Environment
Management acknowledged continued challenges in the export business due to soft commodity prices, muted crop economics, and geopolitical uncertainties, but expressed confidence in the business model and future recovery.
“With respect to our exports business, the operating environment continues to remain challenging.”
- •Erratic weather and climatic situations impacting domestic agri demand“The industry remains cautious and watchful of erratic weather and climatic situations which will impact consumption patterns.”
- •Pricing pressure and high input costs“There are pressure on margins due to high input cost & higher levels of inventory, however we believe consumption patterns will see a positive trajectory.”
- •Geopolitical uncertainties and tariffs affecting exports“This is further compounded by rising costs due to geopolitical uncertainties, genericization pressures and tariffs.”
- •Volatility in raw material prices“While margins remain robust, we continue to closely monitor the operating environment, given the volatility in the raw material prices.”
Business quality remains stable.
Current forensic pressure is elevated and improving.
Key risks remain concentrated in growth sustainability and operating leverage.
The risk profile is Early Signals and currently consolidating. Recent structural triggers in governance suggest a building pressure on the underlying framework. Material forensic traces are visible in structural transparency and audit trails, indicating a progressive erosion of structural stability. Continued monitoring is necessary as risk levels remain above institutional safety parameters.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹1,770, the market expects this company to grow its revenue by 30.2% every year for the next 5 years. If you think the company will grow faster than 30.2%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth significantly above the company's historical delivery. Current market expectations appear demanding relative to the business's track record, resulting in higher expectation risk.
Using the Implied Revenue Model, the market is pricing PIIND for 30.2% implied revenue growth versus 1.8% observed 3Y revenue CAGR. Current expectations appear demanding, and trailing fundamentals provide moderate support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides moderate support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 30.2% | 1.8% | Aggressive |
| Operating Margin (EBIT) | 16.0% | 24.1% | Achievable |
| Free Cash Flow Conversion | -60.7% | 20.3% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance well above the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued stronger profitability and stronger cash generation would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 4 declining phase. Institutional participation has also deteriorated, compounding the weak trend as momentum continues to deteriorate. Current price action does not yet confirm a structural recovery.
What Is Driving Market Structure?
Market behavior remains consistent with deteriorating financial conditions.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & A/D Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on PIIND & 3 market anomalies weekly
See a sample issue →